Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Net Margin (2020 - 2025)

Vivos Therapeutics' Net Margin history spans 6 years, with the latest figure at 181.85% for Q4 2025.

  • Quarterly results put Net Margin at 181.85% for Q4 2025, down 10540.0% from a year ago — trailing twelve months through Dec 2025 was 121.72% (down 4763.0% YoY), and the annual figure for FY2025 was 121.71%, down 4762.0%.
  • Net Margin for Q4 2025 was 181.85% at Vivos Therapeutics, down from 79.61% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 44.15% in Q1 2023 to a low of 181.85% in Q4 2025.
  • The 5-year median for Net Margin is 123.97% (2021), against an average of 114.82%.
  • The sharpest move saw Net Margin soared 17743bps in 2021, then plummeted -10540bps in 2025.
  • Year by year, Net Margin stood at 168.25% in 2021, then increased by 8bps to 154.15% in 2022, then increased by 15bps to 131.13% in 2023, then surged by 42bps to 76.45% in 2024, then plummeted by -138bps to 181.85% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 181.85%, 79.61%, and 131.23% for Q4 2025, Q3 2025, and Q2 2025 respectively.